Discovery of Precision Oncology Drugs
NTRC provides in vitro drug discovery services focused on Precision Medicine. We help you to find the informed route to the clinic. Information can be found at www.oncolines.com
Understanding the clinical resistance to kinase inhibitors
The work presented in this poster elucidates the resistance mechanisms that cancer cell lines develop in vitro to the FGFR kinase inhibitor erdafitinib. Furthermore, it provides insight into inhibitors that are of potential use for treatment of erdafitinib-resistant cancers.